|
業務類別
|
-- |
|
業務概覽
|
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States. |
| 公司地址
| C/ Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000 |
| 電話號碼
| +61 398260399 |
| 傳真號碼
| +61 398240083 |
| 公司網頁
| https://www.opthea.com |
| 員工數量
| 34 |
| Ms. Karen Adams |
Vice President, Finance and Company Secretary |
美元 247.79K |
15/09/2025 |
| Mr. Jeremy M. Levin, D.Phil.,M.B. |
Chairman of the Board and Acting Chief Executive Officer |
-- |
15/09/2025 |
|
|
| Mr. Lawrence B. Gozlan |
Independent Director |
15/09/2025 |
| Mr. Jeremy M. Levin, D.Phil.,M.B. |
Chairman of the Board and Acting Chief Executive Officer |
15/09/2025 |
| Ms. Kathy Connell |
Independent Director |
15/09/2025 |
|
|
|
|
